Clinical Trials | April 14, 2026
AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial
Highlights Mirvetuximab-based regimen promise
Highlights Mirvetuximab-based regimen promise
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The decision is based on the phase 3 DESTINY-Breast11 trial
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The approval is backed by data showing deep, durable responses and manageable tolerability
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
India plays a critical role in Bristol Myers Squibb’s global strategy
Subscribe To Our Newsletter & Stay Updated
